Objectives: Many research indicate that the tardive dyskinesia (TD) is generally linked with long-term antipsychotic therapy for schizophrenia. Glial cell line-derived neurotrophic factor (GDNF) is a critical role in the protection of catecholaminergic, dopaminergic, and cholinergic neurons. Thus, we examined the serum GDNF levels in schizophrenia patients with TD (WTD) and without TD (NTD) and compared with healthy controls (HC), respectively.
| INTRODUCTION
Schizophrenia is a severe mental disorder characterized by acute or chronic psychotic symptoms that affects not only those afflicted with the disease but also the individuals' families, as well as society as a whole (Owen, Sawa, & Mortensen, 2016 ). Yet to date, the causes and pathogenesis of the disease remain relatively unknown. Those with schizophrenia have a large probability for recrudescent psychiatric problems and disabilities in social and professional situations and have a reduced life expectancy and an increased likelihood of health care spending (Akinsulore et al., 2015; Atun, 2015; Carmona, Gómez-Benito, Huedo-Medina, & Rojo, 2017; Chesney, Goodwin, & Fazel, 2014; Mayer-Amberg, Woltmann, & Walther, 2016) . The emergence of antipsychotic drugs in the 1950s, following the finding that chlorpromazine could reduce psychotic episodes, gave those afflicted with psychiatric diseases the first real chance to live normal lives (Abbott, Jaramillo, Wilcox, & Hamilton, 2013; Adams et al., 2005; Haan & Liu, 2009; Shohamy et al., 2010) . As the symptoms of schizophrenia were intermittent, long-term drug therapy was needed to successfully combat the disease (Heilbronner, Samara, Leucht, Falkai, & Schulze, 2016; Novick, Montgomery, Treuer, Moneta, & Haro, 2016) . However, long-term use of antipsychotic drugs was found to have a variety of negative effects on patients, including weight gain, movement disorders, drowsiness, and a sedated physical state Leucht et al., 2012) . For example, movement disorders related to antipsychotic medication included acute extrapyramidal side effects (dystonia, drug-induced parkinsonism, akathisia, and catatonia) and tardive dyskinesia (TD), a potentially irreversible disorder (Carof, Hurford, Lybrand, & Campbell, 2011; Miller et al., 2005; Remington, 2007) . TD was characterized by involuntary, repetitive, and stereotyped choreiform movements that were related to extremities, orofacial muscles, paraspinal muscles, and various other body parts (American Psychiatric Association, 2013) . The emergence of TD was nearly always associated with uninterrupted psychotic medication, and symptoms rapidly decreased when treatment was interrupted, altered, or lessened (Carof et al., 2011) . Therefore, detection of the earliest symptoms of TD and possible treatment options have proved challenging (Remington, 2007) .
Although the function of both the first-generation antipsychotics (FGA) and the second-generation antipsychotics (SGA) involves balancing the ratio of activity of dopamine D2/serotonin 5-HT (2A) receptors and glutamate, SGA have gradually replaced FGA in clinical practice due to their superior outcomes in relieving psychotic symptoms and in eliciting fewer side effects as they emerged (Correll & Schenk, 2008; Parker, 2009 ). However, some research showed that chronic use of many SGA was still associated with onset of TD (Bonham & Abbott, 2008; Divac, Prostran, Jakovcevski, & Cerovac, 2014; Rummel-Kluge et al., 2010; RummelKluge et al., 2012; Woods et al., 2010) , and therefore, uninterrupted use of these medications by schizophrenic patients remains questionable (Correll & Schenk, 2008; Remington, 2007) . Moreover, other mental disorders such as affective disorder and disruptive behavior disorders are also treated with both FGA and SGA (Olfson, Blanco, Liu, Wang, & Correll, 2012) . Hence, it is imperative that clinical research should be done to elucidate effective strategies to reduce antipsychotic-related TD. However, a more basic understanding of how TD develops in response to chronic antipsychotic drug treatment is first needed before clinical research can begin.
Although there have been numerous theories regarding the etiology and pathophysiology of TD, to date, no definitive mechanisms have been identified. Although not proven, it is theorized that the mechanisms of TD involve postsynaptic dopamine hypersensitivity resulting from blockade of dopaminergic receptors on a variety of neurons, including gamma-aminobutyric acid (GABA) and striatal cholinergic neurons, resulting in structural changes in the brain (Margolese, Chouinard, Kolivakis, Beauclair, & Miller, 2005; Sachdev, 2000; Sarro et al., 2013) . In addition, evidence has been found that oxidative stress (OS) and increased free radical formation may contribute to the onset and progression of TD (Cho & Lee, 2013; Elkashef & Wyatt, 1999; Margolese et al., 2005; Sachdev, 2000) . Interestingly, OS has also been linked with abnormal changes in both dopaminergic and GABAergic neurons, as well as brain structure (Cho & Lee, 2013; Olfson et al., 2012; Sachdev, 2000) . Although, these findings regarding the mechanisms involved in the onset and progression of TD remain controversial, and most researchers believe that a combination of factors are responsible (Margolese et al., 2005) . To date, several risk factors associated with the onset of TD have been found, including gender, age, long-term antipsychotic treatment, sex, alcohol or drug abuse, diabetes mellitus, cognitive impairment, and organic brain injuries (Cho & Lee, 2013; Miller et al., 2005; Sachdev, 2000) . In addition, elevated OS is thought to be associated with several risk factors for TD, including advanced age diabetes and drug abuse (Sachdev, 2000; West, 2000; Yamamoto & Raudensky, 2008) .
It is well established that a variety of neurotrophic factors are required to promote the growth, differentiation, and maintenance of neurons (Santos, Gonzalez-Perez, Navarro, & Valle, 2016; Xiao & Le, 2016) . In recent years, neurotrophic treatments have become promising drug candidates for patients suffering from several degenerative diseases (Bezdjian et al., 2016) , and as a result, an increasing number of studies have been performed to identify the role of neurotrophic factors in mental illness. Among these factors, brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor have attracted the most interest among the research community (Airaksinen & Saarma, 2002; Allen, Watson, Shoemark, Barua, & Patel, 2013; Angelucci, Brenè, & Mathé, 2005; Buckley, Pillai, & Howell, 2011; Favalli, Li, Belmonte-de-Abreu, Wong, & Daskalakis, 2012; Ghitza et al., 2010; Green, Matheson, Shepherd, Weickert, & Carr, 2011; Lai et al., 2016; Niitsu et al., 2014; Tunca, Akdede, et al., 2015) . GDNF was first identified as a neurotrophic factor involved in the survival and function of embryonic dopamine neurons in vitro and later in vivo and was subsequently shown to affect other neuronal subpopulations (Airaksinen & Saarma, 2002) .
And unlike the neurotrophin family (nerve growth factor, brainderived neurotrophic factor, etc.), GDNF belongs to the transforming growth factor β superfamily. GDNF interacts with the receptor tyrosine kinase similar to other neurotrophic factors, but it must associate with the GDNF family receptor α for Ret receptors to function in vivo (Allen et al., 2013; Skaper, 2012) . A number of studies have revealed a potential role for GDNF in neurodegenerative disorders as well as neuropsychiatric diseases, such as Alzheimer's disease (AD; Sopova, Gatsiou, Stellos, & Laske, 2014), Parkinson's disease (Esther & Gonzalo, 2011; Mickiewicz & Kordower, 2011) , drug addiction (Esther & Gonzalo, 2011; Ghitza et al., 2010) , stress vulnerability (Uchida et al., 2011) , and mood disorders (Ma, Chen, Zhu, Jia, & Gao, 2013; Takebayashi et al., 2006; Zhang et al., 2010) . To date though, there have been conflicting data regarding GDNF and schizophrenia, with several studies indicating altered serum GDNF levels and others finding no significant changes in levels in schizophrenic patients (Niitsu et al., 2014; Skibinska et al., 2017; Tunca, Akdede, et al., 2015; Xiao & Le, 2016) . Furthermore, no significant associations have been found between genes encoding for GDNF and schizophrenia (Ma et al., 2013; Williams et al., 2007) .
Interestingly though, a positive correlation was found between schizophrenia and GDNF family receptor genes (Souza et al., 2010) . Taken together, these findings suggest that altered GDNF levels may be associated the pathophysiology of schizophrenia.
However, to the best of our knowledge, peripheral GDNF levels have not been measured in schizophrenia accompanied with TD or without TD. Therefore, this study was designed to investigate serum levels of GDNF in chronic schizophrenic patients with and without TD and compare them between the groups, as well as with healthy controls, to find a possible relationship between GDNF and TD in chronic schizophrenia.
| METHODS

| Subjects
Seventy-five males with schizophrenia inpatients from Affiliated WuTaiShan Hospital of Medical College of Yangzhou University, China, were enrolled in the current study. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition, was used as diagnostic criteria for chronic schizophrenia. TD was diagnosed based on the criteria of Schooler and Kane (1982) . Chronic patients were assessed by four separate and skilled clinical psychiatrists. Patients with mental retardation, dementia, affective disorders, substance abuse/dependence, neurological disease (including epilepsy), and diabetes mellitus, as well as heart, liver, and kidney diseases, were excluded. All patients were receiving regular oral antipsychotic drug treatment at the time of the study. Treatment was composed primarily of monotherapy with clozapine (n = 17), risperidone (n = 8), perphenazine (n = 20), sulpiride (n = 11), chlorpromazine (n = 12), and haloperidol (n = 7). Mean antipsychotic doses were taken as chlorpromazine equivalents of 534.67 ± 257.75 mg/day. All patients had been medicated continually for 13.65 ± 6.99 years at the time of the investigation. The average duration of illness was 25.03 ± 7.07 years, and all patients were between 32 and 65 years old. Subjects taking part in this study did not have a history of drug or alcohol abuse or dependence abuse.
In parallel, 53 healthy subjects were recruited from the community in Yangzhou. Healthy volunteers were all in good physical health and had no personal or familial psychiatric history as assessed by
Diagnostic and Statistical Manual of Mental Disorders, fifth edition Axis I psychiatric diagnosis.
This study has obtained the approval of the Ethics Committee of Yangzhou WuTaiShan Hospital before starting. Each subject gave an informed consent on paper after a complete clarification of the study's aim and procedures.
| Serum GDNF level measurements
Venous blood taken from subjects who fasted overnight between 07:30 and 08:30 was collected in tubes without anticoagulant and centrifuged at 3,000 g for 15 min after sampling. Serum was then separated, aliquoted, and stored at −70°C prior to use. GDNF levels in serum were measured using a sandwich enzyme-linked immunosorbent assay according to the manufacturer's instructions (Promega, Madison, WI, USA), and the optical density of each well was scaled using an automated microplate reader (Epoch; BioTek Instruments, Winooski, VT, USA). To determine total GDNF, we first acid-treated and then neutralized the samples according to the manufacturer's instructions before proceeding with the enzyme-linked immunosorbent assay protocol. All samples were analyzed in the same time.
And the patient's and control's samples have been detected altogether on the same plates. All samples were performed in duplicate by researchers who were blinded to the experimental groups. GDNF serum concentrations were depicted as picogram/milliliter. The intra-assay and interassay coefficients of variation were <4% and <5%, respectively.
| Clinical measures
A questionnaire method was used to gather basic data, demographic features, psychological status, and medical history of each subject.
Other information was acquired from their case history. Four skilled trained psychiatrists who did not know the clinical situation of the patients evaluated the severity of TD using the Abnormal Involuntary Movement Scale. Thirty-two subjects who scored ≥2 were placed in the patients group with TD (WTD). The remaining 43 patients were included in the patients group without TD (NTD). At the beginning of this study, the same four clinicians conducted the psychiatric assessment of all participants using the Positive and Negative Syndrome Scale (PANSS). The four evaluators simultaneously received relevant training ahead of the assessment. Finally, all assessments were recorded before laboratory measurements were taken.
| Statistical analysis
Data were analyzed with SPSS 19.0 (IBM, Armonk, NY, USA). Calculations on categorical data were carried out using chi-squared analysis.
The data of continuous variables were normally distributed and homogeneity of variance. Means ± standard deviations (SD) of continuous variables of data were presented and analyzed using one-way analysis of variance, analysis of covariance (ANCOVA), and independent sample t tests. In addition, a power calculation and effect size determination were performed using the G*Power 3.1.9.2 program. The relationship between the two variables was examined using Spearman's correlation coefficient. Differences of P < 0.05 were regarded as significant.
| RESULTS
| Demographic data
The major findings of the study are presented in Table 1 . There was a significant difference between the two patient groups with regard to PANSS negative subscale score (t = 2.522, df = 73, 140, P = 0.014), but not in age, education, smoking status, and duration of illness.
There were no differences in demographic data (education, body mass index, age, and smoking status) among the three groups (P > 0.05).
| Serum GDNF levels
One-way analysis of variance showed that there was a significant difference among the three groups ( F = 4.571, df = 2, 125, P = 0.012) and an effect size of 0.23 with power of 0.71. GDNF levels in TD patients were significantly decreased compared with those in the NTD group as well as healthy controls (P = 0.030 and P = 0.003, respectively), as assessed by least significant difference post hoc (Figure 1) . Following univariate analysis of ANCOVA and controlling for PANSS negative subscale scores as a covariate, GDNF levels remained significantly lower in the WTD group compared with the NTD group ( F = 4.092, df = 2, 75, P = 0.047). Interestingly, no significant decreases in GDNF levels were observed in NTD patients compared with healthy controls (P = 0.454). Lastly, no correlations were found between clinical variances and serum GDNF levels in schizophrenia (P > 0.05).
| DISCUSSION
In this study, decreased GDNF levels were found in chronic schizophrenia (including WTD and NTD) compared with healthy controls.
These decreased GDNF levels were not in agreement with a recently published report in which unchanged levels were found in a Japanese cohort suffering from chronic schizophrenia (Niitsu et al., 2014) . In contrast though, conducted a comparative study of four major psychiatric disorders and detected that in schizophrenia, GDNF levels were decreased compared with mania and healthy controls (Tunca, Akdede, et al., 2015) . Similarly, results regarding GDNF levels have also been found to be inconsistent among studies involving affective disorders. Tunca, Bayın, et al. (2015) found increased serum GDNF levels during acute manic and lower serum GDNF levels during depressive episodes in bipolar patients, whereas Zhang et al. (2014) and Lee et al. (2015) detected lower GDNF levels in major depressive disorder patients compared with healthy controls. Several other studies found that there was a reduced density of glial cells in patients suffering from schizophrenia and mood disorders (Cotter, Pariante, & Everall, 2001; Elsayed & Magistretti, 2015; Niciu, Henter, Sanacora, & Zarate, 2013; Tobe, 2013; Vostrikov, Uranova, & Orlovskaya, 2007; Williams et al., 2013) . The changes in glial cells may result from a weakening of normal trophic support usually provided by neurotrophic factors (Cotter et al., 2001 ). Therefore, loss or injury to glial cells may contribute to a decline in glutamate uptake in patients with mood disorders (Zarate et al., 2003) . Similarly, it was found that there were impaired glutamate-glutamine cycles and glutamatergic disturbances during active episodes in schizophrenia that may have been caused by altered astrocyte activity (Kondziella, Brenner, Eyjolfsson, & Sonnewald, 2007; Marrssman et al., 2013) . Interestingly, concentrations of glutamine were shown to be increased in never treated schizophrenia (Olbrich et al., 2008; Théberge et al., 2007) , whereas its levels were significantly reduced in chronic patients (Ohrmann et al., 2005) . Furthermore, previous data have demonstrated that GDNF provides benefit to the maturation of nerve cells (Santos et al., 2016; Xiao & Le, 2016) and affords protection to dopaminergic neurons (Airaksinen & Saarma, 2002; Granholm et al., 2000; Skaper, 2012) . In astrocytes, GDNF expression is induced by dopaminergic neurons (Saavedra, Baltazar, Santos, Carvalho, & Duarte, 2006), and we therefore speculate that there is a relation between decreased GDNF levels and dopaminergic abnormality in schizophrenia. Overall, FIGURE 1 Serum GDNF levels in WTD, NTD, and HC. WTD: male chronic schizophrenic patients with TD; NTD: male chronic schizophrenic patients without TD; HC: healthy controls; GDNF: glial cell line-derived neurotrophic factor; ANOVA: analysis of variance neuron-glia interaction mechanisms deserve further studies to clarify their role in schizophrenia, which would give possible direction to future clinical studies.
Interestingly, we found significant deviations in GDNF levels between the WTD and NTD groups. In particular, we found that GDNF levels were significantly lower in the WTD group compared with both the NTD and healthy control groups. It is worth noting that there was a significant difference between the two patient groups with regard to PANSS negative subscale score. GDNF levels in the WTD group remained markedly lower compared with the NTD group when we controlled for PANSS negative subscale scores as a covariate; therefore, the result of the ANCOVA indicated that the difference of GDNF levels between the two patient groups was associated with the existence of TD regardless of the severity of negative symptoms.
Although GDNF levels in the NTD group were lower than normal controls, the difference was not significant. These differences of GDNF levels between the three groups may be associated with the pathophysiology of TD in chronic schizophrenia. As mentioned earlier, the mechanism of TD is complicated and undefined, and numerous factors have been implicated in TD onset and progression, including postsynaptic dopamine hypersensitivity, OS, and loss of dopaminergic receptors on GABA and striatal cholinergic neurons (Cho & Lee, 2013; Elkashef & Wyatt, 1999; Margolese et al., 2005; Sachdev, 2000; Sarro et al., 2013) . In particular, the dopamine TD hypothesis considers that decreasing dopamine receptor sensitivity and postsynaptic dopamine hypersensitivity are associated with the antipsychotic TD induction (Margolese et al., 2005; Sachdev, 2000) . As GDNF has been shown to have positive effects on the survival and development of dopamine neurons (Airaksinen & Saarma, 2002; Skaper, 2012) , alterations in GDNF thus can possibly influence dopamine neurons (Kumar et al., 2015) and TD onset. In the current study, although we found decreased GDNF levels in the WTD group compared with the NTD group, these levels were in serum GDNF and not brain-derived GDNF (Kastin, Akerstrom, & Pan, 2003) . Interestingly, Straten, Eschweiler, Maetzler, Laske, and Leyhe (2009) measured GDNF in the cerebrospinal fluid (CSF) of patients with AD and normal controls, then found that there has a strong correlation between GDNF levels in the serum and CSF of normal controls; the authors postulated that movement of GDNF from the periphery into central nervous system was occurring.
In contrast, no correlation between GDNF levels in the serum and CSF of AD patients was found (Straten et al., 2009 ). However, several other studies found no evidence that GDNF could pass through the blood-brain barrier into the central nervous system (Airaksinen & Saarma, 2002; Kastin et al., 2003; Kumar et al., 2015; Luz, Mohr, & Fibiger, 2016) . Thus, we could not accurately determine if serum GDNF levels correlated with brain GDNF. Furthermore, there are many unknown factors that may contribute to the onset of schizophrenia and TD, and further research is required to elucidate them.
In particular, the OS hypothesis has gained increasing attention among the scientific community (Cho & Lee, 2013; Lister, Nobrega, Fletcher, & Remington, 2014) . In 2007, Smith and Cass conducted a study in patients with Parkinson's disease and then found that the effects of GDNF involved the attenuation of free radical damage and a reduction in OS. Therefore, the relation between GDNF and OS in schizophrenia with TD warrants further investigation. Moreover, GDNF was not related to the factors (age, duration, PANSS score, etc.) in our study, which is partly inconsistent with the result of some previous research (Souza et al., 2010) .
There were several limitations to this study that must be taken into account. First, every subject in both patient groups was treated with antipsychotics; thus, an influence of medicine on GDNF levels cannot be rule out. The effects of antipsychotics on GDNF levels have been demonstrated in a previous study, and this effect was related to the type and dosage of the selected drug (Shao, Dyck, Wang, & Li, 2006) . Further studies are required to investigate possible discrepancy using different drug groups and medication-free subjects. Second, we measure serum GDNF levels and not brain-derived GDNF. Whether the alteration of serum GDNF reveals any change in the brain remains to be elucidated. Lastly, only male patients were recruited in the current study and as such do not represent the whole population.
In conclusion, serum GDNF levels were decreased in chronic schizophrenic patients, especially in patients with TD. Whether these results indicate a pathological mechanism of TD in schizophrenia remains to be elucidated. This finding further confirms that various factors are involved in schizophrenia with TD and that alterations in neurotrophic factors are potential mechanisms in the disease. The exact mechanisms and how mechanisms regarding neurotrophic factors influence schizophrenia with TD remain to be seen.
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